The Clinical Research Of Using Both Xuezhikang And Conventional Dose Simvastatin To Treat CHD With Dyslipidosis

Objective: By comparing the research of using both Xuezhikang and conventional-dose simvastatin in decreasing Blood-lipid with the research of using high-dose simvastatin in intensive lipid-lowering, to observe the effects of adjusting blood-lipid, the side effects and the cardiovascular and cerebrovascular events. The result provides a guide for the treatment of hyperlipoidemia with a combination of Chinese and Western medicine.Methods: 60 cases of patients who had coronary heart disease and dyslipidemia that achieve the the standard of intensive lipid-lowering therapy were randomly divided into two groups in accordance with their age and the similar lipid levels. One group was a treatment group which had 30 cases .They were treated by Xuezhikang and conventional-dose simvastatin. The other group was a control group which had 30 cases. They were treated by high-dose simvastatin. The course of treatment was 6 months. Then we observe their lipid-lowering efficacy, side effects and cardiovascular and cerebrovascular events and make a contrast research.Results: After the treatment, both the treatment group and the control group in the lipid-lowering achieved good effect. In decreasing TG, TC, HDL-c, the treatment group had a total effective rate of 86.%, 86.7%, 83.3%, the control group had a total effective rate of 80.0 %, 90.0%, 80.0%. There were no significant difference between the two groups (p> 0.05). Both the treatment of two groups can effectively lower TG, TC, LDL-c and raise HDL-c. The attainment rate of intensive lipid-lowering in the treatment and control groups were 86.7% and 83.3%. There were no significant difference between the two groups (p> 0.05).It showed that both the treatment of two groups can reach the goal of intensive lipid-lowering. There were no significant difference between the two groups in reducing TC,LDL-c and increasing HDL-c (p> 0.05).They both have significant effects. But the study found that there were a significant difference in the reduction of TG between the treatment group and the control group (P <0.05). The treatment group was significantly better than the control group. The extent of declining the blood-lipid showed that TG was declined by 33.0% and 22.5%. TC was decreased by 20.4% and 23.9%. LDL-C was decreased by 31.7% and 33.5%. HDL-C was increased by 19.4% and 18.0%. In the side-effects, the treatment group had one case of gastroenteric reaction. The control group had 2 cases of gastrointestinal reaction and 2 cases of unusual increase in ALT and AST. The two groups were significantly different (p <0.05). The incidence of side effects of the control group was significantly higher than that of the treatment group. Using both Xuezhikang and high-dose simvastatin can reduce the occurrence of side effects. The two groups had no significant difference in the cardiovascular and cerebrovascular events. (p> 0.05).Conclusion: By contrast with using high-dose simvastatin, using both Xuezhikang and conventional dose simvastatin can not only effectively achieve the objectives of intensive lipid-lowering, but also lower the TG level and reduce side effects.